Piper Jaffray analyst Joshua Schimmer says that one abstract from the American College of Gastroenterology published yesterday highlighted the results of the Phase 3 APRON study and potential of the NK-1 receptor antagonist aprepitant for the treatment of gastroparesis. The data show "encouraging signs of efficacy" for the mechanism and suggest a path forward for Vanda Pharmaceuticals' own NK-1 receptor antagonist tradipitant, Schimmer tells investors in a research note. He believes tradipitant represents an underappreciated part of the Vanda story and views the company's potential in gastroparesis as another reason to own the shares. Schimmer reiterates an Overweight rating on Vanda with a $19 price target.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here